Glucosentient Inc.
Champaign, IL
- UEI
- Z1GKW7XKS2P1
- CAGE
- 6LYL0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2109 S Oak St #100b, Champaign, IL 61820, USA
- Website
- glucosentient.com
- Founded
- 2011
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Glucosentient Inc., doing business as Glucosentient, is a for-profit organization that specializes in developing innovative point-of-care diagnostic technologies for various medical applications. The company has been registered to receive federal awards since December 8, 2011, and has successfully secured multiple federal grant awards from agencies within the Department of Health and Human Services. Glucosentient's primary focus appears to be leveraging existing blood glucose meter (BGM) technology to create affordable, easy-to-use diagnostic platforms for a range of health conditions, particularly those relevant to global public health challenges.
Through its federal grant awards, Glucosentient has undertaken several significant research and development projects. The National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a $265,773 grant to develop a point-of-care therapeutic drug monitoring system for anti-tuberculosis drugs, aimed at improving treatment outcomes in resource-limited areas. The National Institute of Dental and Craniofacial Research (NIDCR) provided a $269,000 grant for the development of a salivary cytokine test for early detection of oral cancer, utilizing BGM technology to measure key biomarkers. Additionally, Glucosentient received funding from NIAID to create a rapid point-of-care test for hepatitis C virus core antigen, designed to screen for active HCV infections more efficiently than current two-step procedures. These projects demonstrate Glucosentient's commitment to addressing critical healthcare needs through innovative diagnostic solutions, particularly in the areas of infectious diseases and cancer detection.
Quick answers
Is Glucosentient Inc. registered in SAM.gov?
Glucosentient Inc.'s SAM.gov registration expired on September 9, 2026.
What is Glucosentient Inc.'s CAGE code?
Glucosentient Inc.'s CAGE code is 6LYL0, and its Unique Entity ID (UEI) is Z1GKW7XKS2P1.
What is Glucosentient Inc.'s most recent federal award?
Glucosentient Inc.'s most recent federal grant award is Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system… (R43AI181155), from National Institute of Allergy and Infectious Diseases (NIH), on February 12, 2024.
On GovTribe
See Glucosentient Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors